Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

17.14
-1.4100-7.60%
Post-market: 17.140.00000.00%17:50 EDT
Volume:1.77M
Turnover:31.10M
Market Cap:2.83B
PE:-4.93
High:18.92
Open:18.43
Low:17.07
Close:18.55
52wk High:25.00
52wk Low:6.36
Shares:165.03M
Float Shares:152.00M
Volume Ratio:0.64
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4740
EPS(LYR):-3.4740
ROE:-55.71%
ROA:-31.16%
PB:2.91
PE(LYR):-4.93

Loading ...

BUZZ-Dyne Therapeutics rises after positive data for its muscle wasting drug

Reuters
·
Dec 08, 2025

Dyne Therapeutics Inc - Submission for U.S. Accelerated Approval on Track for Q2 2026

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Inc: Registrational Expansion Cohort (Rec) Met Primary Endpoint

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Announces Positive Topline Results From Phase 1/2 Deliver Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (Dmd)

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Inc - Rec Shows Significant Increase in Dystrophin Expression to 5.46%

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Inc - Z-Rostudirsen Shows Favorable Safety Profile

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Announces Topline Results from DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy

Reuters
·
Dec 08, 2025

Dyne Therapeutics Chief Medical Officer Douglas Kerr Reports Sale of Common Shares

Reuters
·
Dec 06, 2025

Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer Reports Sale of Common Shares

Reuters
·
Dec 06, 2025

Dyne Therapeutics (DYN): Evaluating Valuation Following Promising Clinical Results and New Regulatory Designation

Simply Wall St.
·
Nov 28, 2025

Dyne Therapeutics price target raised to $21 from $12 at Bernstein

TIPRANKS
·
Nov 25, 2025

Dyne Therapeutics Inc : Bernstein Raises Target Price to $21 From $12

THOMSON REUTERS
·
Nov 25, 2025

Dyne Therapeutics Is Maintained at Neutral by JP Morgan

Dow Jones
·
Nov 15, 2025

U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66

Reuters
·
Nov 14, 2025

Stock Track | Dyne Therapeutics Plummets 5.08% Following Oppenheimer's Price Target Cut

Stock Track
·
Nov 13, 2025

Oppenheimer Adjusts Price Target on Dyne Therapeutics to $11 From $13, Maintains Perform Rating

MT Newswires Live
·
Nov 12, 2025

Dyne Therapeutics (DYN) Gets a Hold from Oppenheimer

TIPRANKS
·
Nov 12, 2025

RBC Capital Remains a Buy on Dyne Therapeutics (DYN)

TIPRANKS
·
Nov 07, 2025

Dyne Therapeutics price target lowered to $38 from $41 at Evercore ISI

TIPRANKS
·
Nov 07, 2025

Dyne Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Nov 07, 2025